As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success

Armed with “pipeline in a product” efgartigimod, approved in generalized myasthenia gravis (gMG) as Vyvgart, Argenx is confident it can triumph on its own.

In fact, Argenx chief Tim Van Hauwermeiren thinks his company could serve as a “role model” for future biotech innovators amid an era of midsized biopharma buyouts. But in gMG, the budding company will need to prove its merit against a much larger rival in AstraZeneca's Alexion.